Generic semaglutide
Copies launching where protection has lapsed: Canada (approvals from Apr 2026), India and Brazil (Mar 2026). US protection runs to no earlier than Dec 2031.
3 leading companies in generic semaglutide, one segment of pharma: glp-1 & obesity drugs — Semaglutide, tirzepatide and the next wave: about $132B in 2025 GLP-1 sales, with generics now open in Canada
new market segment · researched 2026-11-14
GLP-1 diabetes drugsWeight-loss (obesity) injectablesOral GLP-1 pillsNext-generation obesity drugsGeneric semaglutideSupply chain, compounding & pharmacy
C
Leading generic semaglutide companies
3 companies, with the scale each source states. Scale is the whole company's unless the row says otherwise.
| Company | Where | What they do | Scale |
|---|---|---|---|
| Apotex APTX.TO ↗ | Toronto, Canada since 1974 | Canadian generic maker. Health Canada approved Apo-Semaglutide (Apr 2026) and Sevmia for weight management (Jun 2026). | revenue: 3.9 CAD billions worldwide sales (Forbes, via Wikipedia) (2023) ↗ |
| Dr. Reddy's Laboratories RDY / DRREDDY.NS ↗ | Hyderabad, India since 1984 | Approved in Canada in April 2026 to sell injectable generic semaglutide, after applying in Feb 2024. | — |
| Sandoz SDZ.SW ↗ | Basel, Switzerland since 1886 | Has applied for generic semaglutide in Canada (diabetes only), not yet approved per source. | — |
CA
In Canada
- 2026-04Health Canada approved injectable generic semaglutide from Dr. Reddy's and Apotex (Apo-Semaglutide) in the same week. ↗
- 2026-06Health Canada approved Apotex's Sevmia (semaglutide) for weight management, ages 12 and up. ↗
- 2026-07Aspen Pharmacare's generic semaglutide was approved for diabetes. Sandoz has applied. Health Canada says Novo's own Plosbrio and Poviztra differ from Ozempic/Wegovy only in name and packaging. ↗
M
The pharma: glp-1 & obesity drugs market
The whole market this segment sits in.
global revenue · world132
↗USD billions (GLP-1 therapies, all indications) · 2025
Growth, segments, risks and every company in pharma: glp-1 & obesity drugs →
Quick answers
- What is generic semaglutide?
- Copies launching where protection has lapsed: Canada (approvals from Apr 2026), India and Brazil (Mar 2026). US protection runs to no earlier than Dec 2031. It is one segment of the pharma: glp-1 & obesity drugs market.
- Who are the leading generic semaglutide companies?
- Apotex (Canada), Dr. Reddy's Laboratories (India), Sandoz (Switzerland).
- Which generic semaglutide companies are publicly traded?
- Apotex (APTX.TO), Dr. Reddy's Laboratories (RDY / DRREDDY.NS), Sandoz (SDZ.SW).
- Which Canadian companies are in generic semaglutide?
- Apotex, Toronto.
- How big is the pharma: glp-1 & obesity drugs market?
- For the whole pharma: glp-1 & obesity drugs market, not this segment alone: global revenue (world) 132 USD billions (GLP-1 therapies, all indications), 2025 — Managed Healthcare Executive.